Use of radioactive substances in diagnosis and treatment of neuroendocrine tumors

Andreas Kjaer1,3 & Ulrich Knigge1,2,3

1Department of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging, Copenhagen, Denmark, 2Departments of Surgery and Endocrinology PE, Copenhagen, Denmark, and 3European NET Centre of Excellence, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark

Abstract

Radionuclides are needed both for nuclear medicine imaging as well as for peptide-receptor radionuclide therapy (PRRT) of neuroendocrine tumors (NET). Imaging is important in the initial diagnostic work-up and for staging NETs. In therapy planning, somatostatin receptor imaging (SRI) is used when treatment is targeted at the somatostatin receptors as with the use of somatostatin analogues or PRRT. SRI with gamma camera technique using the tracer 111In-DTPA-octreotide has for many years been the backbone of nuclear imaging of NETs. However, increasingly PET tracers for SRI are now used. 68Ga-DOTATATE, 68Ga-DOTATOC and 68Ga-DOTANOC are the three most often used PET tracers. They perform better than SPECT tracers and should be preferred. FDG-PET is well suited for visualization of most of the somatostatin receptor-negative tumors prognostic in NET patients. Also 11C-5-HTP, 18F-DOPA and 123I-MIBG may be used in NET. However, with FDG-PET and somatostatin receptor PET at hand we see limited necessity of other tracers. PRRT is an important tool in the treatment of advanced NETs causing complete or partial response in 20% and minor response or tumor stabilization in 60% with response duration of up to 3 years. Grade 3–4 kidney or bone marrow toxicity is seen in 1.5% and 9.5%, respectively, but are completely or partly reversible in most patients. 177Lu-DOTATATE seems to have less toxicity than 90Y-DOTATOC. However, until now only retrospective, non-randomized studies have been performed and the role of PRRT in treatment of NETs remains to be established.

Introduction

The recent focus on precision medicine has led to a need for tumor characterization and diagnosis at the molecular level. This may be obtained by in vitro analysis of biopsies, but can better be obtained using non-invasive imaging with radionuclide-based methods, single photon emission computed tomography (SPECT) or positron emission tomography (PET) [1]. The major advantages of using non-invasive radionuclide imaging is the circumvention of sampling error, that is avoiding the risk of tumor samples not being representative of the tumor burden in the patient. In particular, the risk for not identifying the most aggressive phenotype that typically determines the fate of the patient may lead to delay in relevant therapy. Currently, the grading according to WHO of neuroendocrine tumors (NET) relies on immunohistochemistry of Ki67 to identify the proliferation index in hot spots [2]. Indeed, image-based visualization of the phenotype points to large heterogeneity within the tumor burden making evaluation of a single biopsy unlikely to describe the disease relevantly. Also, when treatment with radionuclides is planned visualization of the treatment target, somatostatin receptors, should be on a whole body basis which is only obtainable with imaging. Together, imaging and radionuclide therapy constitute a theranostic pair where imaging is a companion diagnostic for peptide receptor radionuclide therapy (PRRT).

The backbone of nuclear imaging in NET is somatostatin receptor imaging (SRI), which can be performed both with traditional gamma camera technique or now increasingly with PET. Also other imaging targets have been and are still used for imaging in NET. Among these, 18F-fluorodeoxyglucose (FDG)-PET is of particular interest and will be described below. Other PET tracers such as 11C-5-hydroxytryptophan (11C-5-HTP) and 18F-L-dihydroxyphenylalanine (18F-DOPA) have also been used. However, the latter two are probably of less relevance if PET-based SRI is used which will be discussed below. Also metaiodobenzylguanidine (MIBG) scintigraphy mainly performed with gamma camera technology, that is SPECT, seems of less relevance in the era of PET tracers.
Expression of somatostatin receptors in NET

The majority of gastro-entero-pancreatic (GEP) and broncho-pulmonary NETs overexpresses somatostatin receptors. It has been shown that in particular the somatostatin type 2 receptor (SST2) is upregulated both at the protein [3] and gene expression level [4]. Accordingly, SRI is an efficient way to diagnose, stage and restage NET. The percentage of tumors that overexpress SST2 varies between the different NET with insulinomas being positive in less than 70% while other pancreatic NETs and small intestinal NET being positive in around 90% of cases [5]. Overexpression of somatostatin receptors is used as a target for PRRT which is described in detail below [6]. A positive SRI is accordingly a prerequisite for starting PRRT in these patients.

Somatostatin receptor imaging in NET

For many years, the main SRI radionuclide tracer has been 111In-DTPA-octreotide (OctreoScan®) and in many parts of the world it still is. Early studies found the sensitivity for carcinoids using 111In-DTPA-octreotide to be 88–89% whereas for insulinomas it was only 61% [5,7]. A larger retrospective study of 104 patients had a sensitivity of 91% for detection of primary or recurrent NETs [8], whereas in a large meta-analysis including 720 patients a sensitivity of 111In-DTPA-octreotide for detection of abdominal NETs was 78% (95% confidence interval [CI]: 76–82%) [9]. In early studies, the optimal dose of tracer was not determined. Using what is currently considered state-of-the-art procedures has shown to increase the value of the investigation [10]. According to procedure guidelines of the European Association for Nuclear Medicine, somatostatin receptor scintigraphy with 111In-DTPA-octreotide should include imaging at two time points, either 4 h and 24 h or 24 h and 48 h [11]. Imaging at 48 h is particularly useful if intestinal focus is seen after 24 h to discriminate between a true focus and intestinal secretion, in the latter case movement of disappearance of the focus is likely. Since lesions that are seen after 4 h are normally also seen after 24 h we do not perform 4 h imaging routinely at our institution. Also, we do not pause somatostatin analogues since data do not support this is necessary [11]. However, use of laxatives may be beneficial. The investigation should always include a SPECT mostly performed as a SPECT/CT. At our hospital, SPECT/CT is normally performed 24 h after tracer injection. When 111In-DTPA-octreotide is performed in accordance with all these recommendation, an overall sensitivity of 89% was recently found by us in a study of 96 patients [12]. In this study, we performed an analysis of sensitivity based on Ki67 grading. As expected, tumors with Ki67 >15% were only positive in 69% of the cases, whereas tumors with Ki67 at or below 15% were detected in 90% of the cases indicating the more well-differentiated nature of the latter with somatostatin receptor expression. Interestingly, sensitivity did not differ with tumor origin. Whereas a huge amount of studies have been performed using 111In-DTPA-octreotide, only few other gamma camera suited somatostatin receptor ligands have been tested. Most notably, 99mTc-EDDA/HYNIC-Tyr3-octreotide have been tested both in carcinoid tumors [13] and in gastro-entero-pancreatic (GEP) NETS [14] but without being better than 111In-DTPA-octreotide. Accordingly, these alternative gamma camera tracers never established themselves to any larger extent and currently SRI with 111In-DTPA-octreotide remains the primary tool for staging of NETs.

From SPECT to PET somatostatin receptor imaging

Development of PET technology together with the rapidly increasing availability worldwide of PET and recently more often PET/CT scanners has also moved nuclear imaging of NETs from gamma camera-based imaging to PET imaging.

Advantages of PET includes the substantially higher sensitivity (>100-fold) compared with SPECT translating into images with less noise obtained a lower radiation dose. Also, the spatial resolution is much better for PET compared with SPECT. On average, modern SPECT scanners are capable of spatial resolution of 8 mm whereas that of PET scanners is 4 mm. This is not the same as not being able to detect smaller foci if they are sufficiently active. Therefore, the increased sensitivity of PET also helps detecting small foci of few mm. Finally, better attenuation is possible with PET scanners, due to the physics of positron emitters. This translates into PET being a quantitative method where changes in uptake, typically expressed as standardized uptake values (SUV), can be detected if larger than 10%. This opens the possibility for early detection of response to therapy, or more importantly of non-response.

Although PET/CT scanners are more expensive than comparable SPECT/CT scanners, the more efficient workflow, for example imaging once 1 h after tracer injection with 68Ga-based SRI in contrast to 2-day protocol with SPECT, may in fact lead to lower overall cost of the investigation when labor cost is included. If effectively used, the investment in scanners is not the major cost of performing nuclear scans.

Whereas running cyclotrons and radiochemistry facilities may be costly, recently PET isotopes produced by generators have gained popularity. Most notably, 68Ga can be obtained from a generator and therefore many 68Ga-labeled compounds are currently emerging. Another way to circumvent the need of a cyclotron is to buy and use long-lived isotopes as 64Cu with a half-life of 13 h. The compound is cyclotron produced but can be used for labeling compounds centrally and from there be distributed widely. The shelf life of a typical 64Cu-labeled PET tracer, for example 64Cu-DOTATE, is 24 h.

PET imaging of somatostatin receptors

68Ga-labeled PET tracers

As discussed above, PET tracers and PET imaging have advantages over SPECT methodology. Accordingly, it was not surprising that several 68Ga-labeled somatostatin receptor ligands have been introduced. Most of these tracers are based on the same peptide ligands as for SPECT, namely octreotide and octreotate. Although they differ somewhat with affinity for the SST2 as well as one of the ligands, 68Ga-DOTANOC, also has some affinity toward especially SST5, clinical data...
on performance of the three most commonly used 68Ga-based tracers, 68Ga-DOTATATE, 68Ga-DOTATOC and 68Ga-DOTANOC, at large has shown no major differences. This might not be surprising, as we found that the gene-expression level that SST2 is expressed at a much higher level than the other SSTs. Also, the tumor-to-background ratios are comparable with the three tracers [3].

We recently published a review where the diagnostic performance of the three 68Ga-based PET tracers was covered in detail [15]. In brief, sensitivity on a patient basis for 68Ga-DOTATATE was reported to be 72–96% based on six studies with total of 144 patients [16–20]. 68Ga-DOTATOC had a diagnostic sensitivity of 92–100% based on six studies with total of 211 patients [21–26]. Finally, 68Ga-DOTANOC had a diagnostic sensitivity of 68–100% based on nine studies with total of 1677 patients [19,20,27–32]. Based on these data, it was also concluded in the review that no major differences between the three common 68Ga-based tracers were documented. However, of more interest might be the studies that compared on a head-to-head basis and two of the PET tracers. Unfortunately these studies are few. Thus, at present only three such studies are available [19,20,33]. Relevantly, these studies focus not on evaluation on a patient basis, where differences would be rather unlikely, but on lesion-based comparisons. Two of the investigations aimed at comparing 68Ga-DOTANOC with 68Ga-DOTATATE [19,20], whereas the last study was on 68Ga-DOTATOC compared with 68Ga-DOTATATE [33]. None of the studies reported any major differences further supporting the equal performance of the tracers. Accordingly, the choice of tracer seems to rely on local availability, experience with one particular tracer and utility in theranostic pairing with PRRT. However, if comparing absolute values as SUV longitudinally, for example for therapy monitoring, using the same tracer seems logical. Also, at least conceptually it may be more meaningful to use 68Ga-DOTATATE for pre-PRRT imaging prior to 177Lu-DOTATATE administration and more meaningful to use 68Ga-DOTATOC prior to 90Y-DOTATATE PRRT. However, whether this is really of importance has to be proven and in many centers other combinations are seen.

Apart from the three most used 68Ga-based somatostatin receptor PET tracers, 68Ga-DOTA-lanreotide (68Ga-DOTALAN) has been used for imaging. The major purpose with this tracer was to serve as companion diagnostics for 90Y-labeled lanreotide. However, two studies comparing 68Ga-DOTALAN head-to-head with 68Ga-DOTATATE [34] or 68Ga-DOTATOC [35] found a clearly poorer performance of 68Ga-DOTALAN for lesion detection. Accordingly, as an imaging agent perse, 68Ga-DOTALAN is not expected to gain any larger use.

64Cu-labeled PET tracers

There are many advantages of using 64Cu instead of 68Ga. First, the half-life of 64Cu is 13 h whereas that of 68Ga is only 1 h. Therefore, delayed imaging is not possible with 68Ga whereas it is possible with 64Cu. Accordingly, we performed a first-in-human study using 64Cu-DOTATATE, where we found that imaging after 3 h was better than 1 h since most kidney activity was cleared at the later time-point [36]. However, as important the differences in physical properties where the positron range, the distance a positron travels from emission till it is annihilated end emits two photons, is very different between 64Cu and 68Ga. For 64Cu mean positron range is 1 mm whereas it is 4 mm for 68Ga. Since what really should be detected is where the positron is emitted, a larger positron range leads to blurring of the image with accordingly lower spatial resolution. This again, could lead to detection of smaller foci by 64Cu. However, currently no head-to-head comparison between 64Cu- and 68Ga-based SRI has been published. Therefore, whether the theoretical advantage translates into clinical differences still remains to be proven. A third advantage of 64Cu-DOTATATE is its shelf-life of more than 24 h, which makes it possible to produce centrally and distribute throughout Europe. Also, the workflow is less sensitive to scheduling of patients than 68Ga-based tracers, which have to be produced shortly before administration and several times a day.

In 2012, we reported data from our first-in-human study including 14 patients who had a head-to-head comparison with 111In-DTPA-octreotide performed [36]. The major finding was that in 6 of 14 patients additional lesions were found with 64Cu-DOTATATE compared with 111In-DTPA-octreotide. Moreover, in five patients the additional foci were in organ systems not previously known as involved. However, more foci are not necessarily true why we performed an 18-month follow-up. During the follow-up, all additional lesions found with 64Cu-DOTATATE were confirmed as true positive. In 2013, we presented data from the first 100 patients where we found a sensitivity of 91% for 64Cu-DOTATATE for detecting NET. Thirty-five cases had 64Cu-DOTATATE identified foci in organs not shown at 111In-DTPA-octreotide (Figure 1). The majority (31 of 35) were later confirmed as true positive lesions [37]. Therefore, we concluded that 64Cu-DOTATATE seems promising for clinical use.

The only other 64Cu-labeled somatostatin receptor ligand that has been tested in humans is 64Cu-TETA-octreotide. In a
small study of eight patients, it was found that compared with $^{111}$In-DTPA-octreotide more lesions were found in 2 of 8 patients [38]. However, no further clinical data have emerged on this tracer since the initial report.

**Other radionuclide tracers for NET imaging**

$^{11}C$-$5$-HTP

$^{11}C$-5-HTP is a serotonin precursor for PET imaging. It is transported into the NET cells via the $L$-type large neutral amino acid transport system (LAT) and in the cell, decarboxylized to serotonin and transported into secretory vesicles by vesicular monoamine transporter.

$^{11}C$-labeling has many obvious advantages including abundance of carbon in biological molecules and the ability to obtain high specific activities. Accordingly, much of the early PET research was performed with $^{11}C$-labeled compounds. However, as PET is now a routine tool for diagnostic workup and follow-up, the rather short half-life of 20 min becomes a challenge with the need of an on-site cyclotron and essentially one production has to be done per patient (maybe two if two scanners are available). Therefore, $^{11}C$-5-HTP PET scan capacity is limited. Also, very limited data on the performance are available. In brief, only three studies including a total of 54 patients have been reported [39–41]. From these studies, a pooled a sensitivity of 87% (95% CI: 75–95%) was calculated [9].

One study on 42 NET patients compared $^{11}C$-5-HTP with $^{111}$In-DTPA-octreotide and described that in 58% of NET patients additional foci were found using $^{11}C$-5-HTP [40]. It must be noted that differences in detection rate mainly must be ascribed to difference between PET and SPECT technology. Another investigation compared $^{11}C$-5-HTP with $^{111}$In-DTPA-octreotide as well as $^{18}F$-DOPA (see below) [41]. It was concluded that $^{11}C$-5-HTP was best in pancreatic islet cell tumors of which 23 were present in the study material but that $^{18}F$-DOPA was best for staging in small intestinal NET (n = 24). Accordingly, $^{11}C$-5-HTP may have a particular role in insulinomas where somatostatin receptors are only expressed in 60–70% of cases.

$^{18}F$-DOPA

$^{18}F$-DOPA, a dopamine precursor and PET tracer, is also taken up by NET cells by LAT and metabolized into dopamine. In the secretory vesicles, dopamine is further metabolized to norepinephrine and epinephrine.

An early meta-analysis of 116 patients based on available studies at that time found a pooled sensitivity for GEP and pulmonary NETs on a patient basis to be 87% (95% CI: 80–93%) [9]. However, PET-based SRI also performs well in these types of NET. Therefore, of more interest is the head-to-head comparison with PET-based SRI. Three such studies are available. Studies that compared with $^{68}$Ga-DOTANOC or $^{68}$Ga-DOTATOC found substantially less lesions with $^{18}F$-DOPA than with the somatostatin receptor ligands [27,42]. Surprisingly, this was true even for pheochromocytomas. Since insulinomas are often somatostatin receptor negative, specific imaging ligands for insulinomas targeting the glucagon-like peptide 1 receptor have been developed. So far, both tracers for gamma camera imaging ($^{111}$In-exendin-4) and for PET imaging ($^{68}$Ga-exendin-4) have been tested in humans [43–46], but the exact value remains to be established.

In the era of PET-based SRI, especially with the $^{68}$Ga-labeled variants, it is not obvious that $^{18}F$-DOPA adds to imaging of NETs. However, it cannot be ruled out that in selected challenging cases $^{18}F$-DOPA may find foci not detected otherwise.

$^{123}$/131$^\text{I}$-MIBG

MIBG is a “false” neurotransmitter handled in the same way by the presynaptic reuptake mechanism of cathecholaminergic nerve terminals. For SPECT, MIBG is labeled with $^{123}$I and for therapy with the $\beta$-emitter $^{131}$I. Although the latter can also be used for SPECT imaging, it is not optimal with standard collimators mounted on the imaging systems.

A pooled sensitivity for $^{123/131}$I-MIBG SPECT imaging based on 125 patients with pulmonary or GEP NETs was found to be 63% (95% CI: 54–72%) [9]. In line with this, SRI is preferred for this indication. However, for pheochromocytomas, neuroblastomas and paragangliomas, somewhat higher sensitivities were reported: 79% (nine studies; n = 161; 95% CI: 68–82%), 84% (five studies; n = 204; 95% CI: 79–89%) and 69% (four studies; n = 87; 95% CI: 58–78%), respectively. However, with PET-based SRI and FDG-PET available it is questionable whether MIBG imaging has any additional value. To evaluate this, we recently published a prospective, head-to-head comparative study with 96 consecutive NET patients. In brief, we performed $^{123}$I-MIBG, $^{111}$In-DTPA-octreotide SPECT and FDG-PET in random order in all patients within a short time frame [12]. Overall, $^{123}$I-MIBG only had a sensitivity of 52%, although SPECT was applied in all studies. Furthermore, only half of the lesions detected by $^{111}$In-DTPA-octreotide were found by $^{123}$I-MIBG. In three cases were $^{123}$I-MIBG positive and $^{111}$In-DTPA-octreotide negative, but all these discrepant cases were also FDG-PET positive. Therefore, no lesions were only seen with $^{123}$I-MIBG. Based on these results, we therefore suggest that $^{123}$I-MIBG has no role in NET imaging apart from companion diagnostics for $^{131}$I-MIBG therapy.

$^{111}$In/$^{68}$Ga-exendin-4

Since insulinomas are often somatostatin receptor negative, specific imaging ligands for insulinomas targeting the glucagon-like peptide 1 receptor have been developed. So far, both tracers for gamma camera imaging ($^{111}$In-exendin-4) and for PET imaging ($^{68}$Ga-exendin-4) have been tested in humans [43–46], but the exact value remains to be established.

$^{18}F$-FDG

FDG is a glucose analogue transported into the cells by means of glucose transporters. Once taken up by the cell, FDG is phosphorylated by hexokinases but, in contrast to phosphorylated glucose, not further metabolized and therefore trapped in the cell where it accumulates. Accordingly, the accumulation of FDG reflects glycolytic activity. FDG-PET has been a game-changer within diagnosis, staging and therapy monitoring in many cancer forms. However, for many years it was not used in NETs due to the reported low
sensitivity. Indeed, it is correct that the sensitivity for detection of NETs is low for FDG-PET. We performed a prospective study in almost 100 consecutive NET patients and found a sensitivity of 58% [12]. The sensitivity was different depending on grading and proliferation index: 41% when Ki67 <2% and 92% for NETs with Ki67 at or above 15%. Accordingly, FDG-PET has the highest sensitivity in highly proliferating NETs where SRI performs the poorest. In line with this, we found 111In-DTPA-octreotide negative patients; of these, 7 were FDG-PET positive. Accordingly, FDG-PET can be used when SRI is negative. However, for diagnosing and staging FDG-PET is probably not the most promising application in NET. However, we reported in the first prospective study on FDG-PET in NET that FDG-PET was a strong prognostic factor. Indeed, we found that FDG-PET positivity was stronger than currently used Ki67 classification [47]. An explanation for the strength of FDG-PET is probably the circumvention of sampling error as whole-body evaluation is performed by imaging, whereas Ki67 is performed on single or few biopsies. As current treatment guidelines rely heavily on aggressiveness of NETs for selection of therapy [6], we suggest that FDG-PET might be better than Ki67 for such decisions. However, this remains to be proven.

Peptide receptor radionuclide therapy in NET

More than 80–90% of NETs express somatostatin receptors, in particular SST2 receptors, as shown by high uptake of somatostatin analogues coupled tracers at tumor cells [3,12]. This has within the last two decades been increasingly utilized for the treatment of patients with advanced metastatic NETs with PRRT [48–51].

The first radionuclide used was 111In-DTPA-octreotide which is an Auger emitter. However, the tumor response was nil or at best modest [52,53]. Much better results have been obtained with the β-emitter 90Y-DOTATOC or the β- and γ-emitter 177Lu-DOTATATE. The advantage of 177Lu-DOTATATE compared with 90Y-DOTATOC is that 177Lu is also a γ-emitter allowing dosimetry to be performed and that the somatostatin analogue octreotide has higher affinity for SST2 receptors than octreotide.

90Y has a maximal tissue penetration of 12 mm and its half-life is 2.7 days, whereas the corresponding values for 177Lu are 2 mm and 6.7 days. Theoretically, the deeper penetration of 90Y should give a better effect in large tumors compared with 177Lu, but clinical data have not yet verified that. However, combination of treatments with 90Y and 177Lu may be more effective than individual treatment with either 90Y or 177Lu [54,55].

Tumor response to PRRT

All studies published to date are retrospective with no randomization. Furthermore, patients selected for PRRT varies from study to study concerning performance status, tumor type, tumor load as well as disease state at time of PRRT initiation. Following treatment with 90Y or 177Lu generally complete response is seen in <5%, partial response in 10–35%, minor response + stable disease in 50–80% and progressive disease in 10–20% [48–51] (Figure 2). Thus, rather large differences exist between the studies performed regarding tumor response, which may be caused by the reasons mentioned above as well as dose and/or treatment cycles used. In general, a tumor response may be seen up to 6–12 months after PRRT. Pancreatic NET seems to respond better to PRRT than small intestinal NET [51]. Best tumor response is found in patients with high uptake at SRI, minor liver tumor load and high Karnofsky performance score [48,50].

Duration of response to PRRT also differs between studies with a median progression-free survival ranging from 15 months to more than 30 months [48,49,51,56,57] and a median overall survival ranging from almost 30 to 50 months [48,49,51,56,57]. This may have the same explanations as mentioned above or be caused by adding other anti-tumor treatments or not in the post-PRRT observation period.

Prerequisites for PRRT are uptake in tumor and metastases at SRI higher than physiological liver uptake, normal kidney functioning, normal bone marrow, limited amount of bone metastases and high PS. For 90Y, normally two to three cycles are given with intervals of 6–8 weeks and for 177Lu normally four cycles are administered with 8 week-intervals [48–51]. More cycles can be added depending on toxicity to the bone marrow and/or kidneys, which are the limiting factors for further treatment cycles.

Side effects of PRRT

Acute side effects include nausea and vomiting, which are related to the concomitant infusion of amino acids for kidney protection. Therefore, all patients receive prophylactic antiemetics during treatment. Abdominal pain and fatigue is occasionally seen [58,59]. In few cases, mild carcinoid crisis is seen and can be sufficiently treated with small doses of octreotide (e.g. 100 µg iv).

Later developed and more severe side effects are renal and bone marrow toxicities. In a recent study of more than 800 patients having PRRT [58], temporary or persistent renal toxicity of any grade was reported to occur in about 35% of the patients of which only 1.5% had grade 3-4 toxicity. Persistently reduced kidney function was seen in 35%. Treatment with 90Y more frequently caused nephrotoxicity than 177Lu, which may be related to the deeper tissue penetration of 90Y. Risk factors for kidney damage are hypertension, hemoglobin toxicity, diabetes mellitus and previous chemotherapy. During PRRT,
concomitant infusion of amino acids is given to protect against kidney toxicity.

The radiation to bone marrow during PRRT may cause bone marrow toxicity causing reduction in platelets, leukocytes and hemoglobin [48,49,58]. However, the toxicity is generally mild and temporary having a nadir about 4 weeks after the last treatment. Grade 1 and 2 toxicity is seen in about 80% and grade 3 and 4 toxicity in about 10%. Bone marrow toxicity occurs significantly more rarely in patients treated with $^{177}$Lu than with $^{90}$Y [58]. Development of myelodysplastic syndrome or leukemia is seen in less than 1% of patients receiving PRRT [48,51,58].

### Conclusion

Imaging of somatostatin receptors remains the backbone of diagnostic work-up and staging in NET patients. Whereas $^{111}$In-DTPA-octreotide has served well for many years, more recently PET tracers are increasingly used. Mainly, $^{68}$Ga-DOTATOC, $^{68}$Ga-DOTATATE and $^{68}$Ga-DOTANOC are used and all perform clearly better than $^{111}$In-DTPA-octreotide. No major differences between the three PET tracers have been documented. In addition, we recently introduced $^{64}$Cu-DOTATATE as an alternative PET tracer with longer half-life and better spatial resolution than $^{68}$Ga-labeled analogues. Future studies will show whether the theoretical advantages of the latter translates into improved clinical utility. Moreover, FDG-PET has recently been documented to be valuable in SRI-negative patients and for evaluation of aggressiveness of NETs. We foresee that FDG-PET may become important for selecting and tailoring therapy in NETs. With FDG-PET and PET-based somatostatin receptor ligands available, there is probably marginal additional value of $^{11}$C-5-HTP, $^{18}$F-DOPA and $^{123}$I-MIBG.

PRRT is an effective treatment of NET patients causing tumor response in 20% and tumor stabilization in 60% with a duration of up to 3 years. The effect of PRRT is at least equivalent to the effect of medical treatments, although surpassed by the results after curative intended surgery [60]. Furthermore, most serious side effects are relatively mild, rare and mostly at least partly reversible. However, at present we don’t know where PRRT should be placed in the hierarchy of treatments for NET. Whether PRRT should be first- or fourth-line treatment is unknown but currently is dependent on the availability of the treatment at the individual NET centers. Studies investigating the effect of PRRT are retrospective and we are looking forward to the results of the ongoing randomized prospective studies.

### Declaration of interest

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

### References

[1] Kjaer A. Molecular imaging of cancer using PET and SPECT. Adv Exp Med Biol 2006;587:277–84.
[2] Hamilton SR, Aaltonen LA. World Health Organization. WHO classification of tumors. Pathology and genetics. Tumours of the digestive system. Lyon: IARC; 2000.
[3] Reubi JC, Waser B, Schaar JC, Laisse JA. Somatostatin receptor ss1-ss5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med 2001;28:836–46.
[4] Binderup T, Knigge U, Mellon Mogensen A, Palnaes Hansen C, Kjaer A. Qualitative gene expression of somatostatin receptors and noradrenaline transporter underlying scintigraphic results in patients with neuroendocrine tumors. Neuroendocrinology 2008;87:223–32.
[5] Krenning EP, Kwakkelboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY, et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993;20:716–30.
[6] Öberg K, Knigge U, Kwakkelboom D, Perren A. Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012;23:vii124–30.
[7] Jamar F, Fiasse R, Leners N, Pauwels S. Somatostatin receptor imaging with indium-111-pentetreotide in gastroenteropancreatic neuroendocrine tumors: safety, efficacy and impact on patient management. J Nucl Med 1995;36:542–9.
[8] Raderer M, Kurtaran A, Leimer M, Angelberger P, Niederle B, Vierhapper H, et al. Value of peptide receptor scintigraphy using (123)I-vasoactive intestinal peptide and (111)In-DTPA-D-Phe1-octreotide in 194 carcinoid patients: Vienna University Experience, 1993 to 1998. J Clin Oncol 2000;18:1331–6.
[9] Koopmans KP, Neels ON, Kema IP, Elsinga PH, Links TP, de Vries EG, et al. Molecular imaging in neuroendocrine tumors: molecular uptake mechanisms and clinical results. Crit Rev Oncol Hematol Elsevier 2009;71:199–213.
[10] Lu S, Gnanasegaran G, Buscombe J, Navalkissoor S. Single photon emission computed tomography/computed tomography in the evaluation of neuroendocrine tumours: a review of the literature. Nucl Med Commun 2013;34:98–107.
[11] Bombardieri E, Ambrosini V, Aktolun C, Baum RP, Bishof-Delaloye A, Del Vecchio S, et al. 111In-pentetreotide scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging 2010;37:1441–8.
[12] Binderup T, Knigge U, Loft A, Mortensen J, Pfeifer A, Federspiel B, et al. Functional imaging of neuroendocrine tumours: a head-to-head comparison of somatostatin receptor scintigraphy, 123I-MIBG scintigraphy, and 18F-FDG PET. J Nucl Med Soc Nucl Med 2010;51:704–12.
[13] Haug A, Auernhammer CJ, Wängler B, Tiling R, Schmidt G, Vierhapper H, et al. Value of peptide receptor scintigraphy using 111In-DTPA-D-Phe1- and 123I-Tyr3-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993;20:716–30.
[14] Hubalewska-Dydejczyk A, Fröss-Baron K, Mikojadczak R, Macek HR, Huszno B, Pach D, et al. 99mTc-EDDA/HYNIC-octreotate scintigraphy, an efficient method for the detection and staging of carcinoid tumours: results of 3 years’ experience. Eur J Nucl Med Mol Imaging 2006;33:1123–33.
[15] Johnbeck CB, Knigge U, Kjaer A. Somatostatin receptor imaging using PET tracers of neuroendocrine tumors; current status and review of the literature. Future Oncol 2011;10:2259–89.
[16] Kayani I, Bomjan JB, Groves A, Conway G, Gacinkovic S, Win T, et al. Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1, Tyr3-octreotate) and 18F-FDG. Cancer 2008;112:2447–55.
[17] Kayani I, Conroy BG, Groves AM, Win T, Dickson J, Caplin M, et al. Intraindividual comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in pulmonary neuroendocrine tumors. J Nucl Med 2000;41:1927–32.
[18] Hang A, Auernhammer CJ, Wängler B, Tiling R, Schmidt G, Göke B, et al. Intraindividual comparison of 68Ga-DOTATATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2009;36:765–70.
[19] Kabasakal L, Demirci E, Ocak M, Decristoforo C, Araman A, Ozsoy Y, et al. Comparison of Ga-DOTATATE and Ga-DOTANOC PET/CT imaging in the same patient group with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2012;39:1271–7.
A. Kjaer & U. Knigge

Cas Rep Plast Surg Hand Surg, 2015; 50(6):740–747

[20] Wild D, Bomanji JB, Benkert P, Maccek H, Ell PJ, Reubi JC, et al. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors. J Nucl Med 2013;54:364–72.

[21] Hofmann M, Maccek H, Börner R, Weckesser E, Schöffski P, Oel L, et al. Biokinetics and imaging with the somatostatin receptor PET radioligand (68Ga)DOTATOC: preliminary data. Eur J Nucl Med 2001;28:1751–7.

[22] Koukouraki S, Strauss LG, Georgoulias V, Schuhmacher J, Haberkorn U, Karkavitsas N, et al. Evaluation of the pharmacokinetics of 68Ga-DOTATOC in patients with metastatic neuroendocrine tumors scheduled for 90Y-DOTATOC therapy. Eur J Nucl Med Mol Imaging 2006;33:460–6.

[23] Suchmann I, Henze M, Engelbrecht S, Eisenhut M, Runz A, Schröder M, et al. Comparison of 68Ga-DOTATOC PET and 111In-DTPAOAC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Mol Imaging 2007;34:1617–26.

[24] Gabriel M, Decristoforo C, Kendler D, Dobrozsuzk G, Heute U, Uprimny C, et al. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 2007;48:508–18.

[25] Putzer D, Gabriel M, Henninger B, Kendler D, Uprimny C, Dobrozsuzk G, et al. Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy. J Nucl Med 2009;50:1214–21.

[26] Versari A, Camellini L, Carlinfante G, Frasoldati A, Nicoli F, Grassi E, et al. Ga-68 DOTATOC PET, endoscopic ultrasonography, and multidetector CT in the diagnosis of duodenopancreatic neuroendocrine tumors: a single-centre retrospective study. Clin Nucl Med 2010;35:321–8.

[27] Ambrosini V, Tomassetti P, Castellucci P, Campana D, Montini G, Rubello D, et al. Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours. Eur J Nucl Med Mol Imaging 2008;35:1431–8.

[28] Ambrosini V, Castellucci P, Rubello D, Nanni C, Musto A, Allegri V, et al. 68Ga-DOTA-NOC: a new PET tracer for evaluating patients with bronchial carcinoid. Nucl Med Commun 2009;30:281–6.

[29] Naswa N, Sharma P, Kumar A, Nazar AH, Kumar R, Chumber S, et al. Gallium-68-DOTA-NOC PET/CT of patients with gastroenteropancreatic neuroendocrine tumors: a prospective single-center study. AJR Am J Roentgenol 2011;197:1221–8.

[30] Krausz Y, Freedman N, Rubinstein R, Lavie E, Orevi M, Tsihori S, et al. 68Ga-DOTA-NOC PET/CT imaging of neuroendocrine tumors: comparison with 111In-DTPA-octreotide (OctreoScan®). Mol Imaging Biol 2011;13:583–93.

[31] Naswa N, Sharma P, Soundararajan R, Karonanizhi S, Nazar AH, Kumar R, et al. Diagnostic performance of the somatostatin receptor PET/CT using 68Ga-DOTATOC in gastrinomas patients with negative or equivocal CT findings. Abdom Imaging 2013;38:552–60.

[32] Ambrosini V, Campana D, Tomassetti P, Fanti S, Ga-labelled peptides for diagnosis of gastroenteropancreatic NET. Eur J Nucl Med Mol Imaging 2012;39:S52–60.

[33] Poeppeel TD, Binse L, Petersen S, Lahner H, Schott M, Antonch G, et al. 68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors. J Nucl Med 2011;52:1864–70.

[34] Demirici E, Ocam K, Kabakalak L, Araman A, Ozsoy Y, Kamanz B. Comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-LAN PET/CT imaging in the same patient group with neuroendocrine tumours: preliminary results. Nucl Med Commun 2013;34:727–32.

[35] Leong D, Kroske A, Waitz D, Gabriel M, Traub-Weidinger T, Uprimny C, et al. Somatostatin receptor PET in neuroendocrine tumours: 68Ga-DOTA0,Tyr3-octreotide versus 68Ga-DOTA0–lanreotide. Eur J Nucl Med Mol Imaging 2013;40:364–72.

[36] Pfeifer AK, Gregersen T, Grønbæk H, Hansen CP, Müller-Brand J, Herskind Bruun K, et al. Peptide receptor radionuclide therapy with Y-DOTATOC and (177)Lu-DOTATOC in patients with neuroendocrine tumor. Q J Nucl Med Mol Imaging 2010;54:68–75.

[37] Wild D, Mäcke H, Christ E, Gloor B, Reubi JC. Glucagon-like peptide 1-receptor scans to localize occult insulinomas. N Engl J Med 2008;359:766–8.

[38] Wild D, Christ E, Caplin ME, Kurzawinski TR, Forrer F, Brändle M, et al. Glucagon-like peptide-1 versus somatostatin receptor targeting reveals 2 distinct forms of malignant insulinoma. J Nucl Med 2011;52:1073–8.

[39] Selvaraju RK, Velikyan I, Johansson L, Wu Z, Todorov I, Shively J, et al. In vivo imaging of the glucagon-like peptide 1 receptor in the pancreas with 68Ga-labeled DOTA3-extendin-4. J Nucl Med 2013;54:1458–63.

[40] Eriksson O, Velikyan I, Selvaraju RK, Kandel F, Johansson L, Antoni G, et al. Detection of metastatic insulinoma by positron emission tomography with [68Ga]extendin-4—a case report. J Clin Endocrinol Metab 2014;99:1519–24.

[41] Binderup T, Knuge U, Loft A, Federspiel B, Kjaer A. 18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors. Clin Cancer Res 2010;16:978–85.

[42] Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 2008;26:2124–30.

[43] Ihmof A, Brunner P, Marincek N, Briel M, Schindler C, Rasch H, et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol 2011;29:2416–23.

[44] Bodei L, Cremonei M, Grana CM, Fazio N, Iodice S, Baio SM, et al. Peptide receptor radionuclide therapy with 111In-DTPA-octreotide: the IEO phase I-II study. Eur J Nucl Med Mol Imaging 2011;38:2125–35.

[45] Pfeifer AK, Gregersen T, Grønbæk H, Hansen CP, Müller-Brand J, Herskind Bruun K, et al. Peptide receptor radionuclide therapy with Y-DOTATOC and (177)Lu-DOTATOC in advanced neuroendocrine tumor: results from a Danish cohort treated in Switzerland. Neuroendocrinology 2011;93:189–96.

[46] Valkema R, de Jong M, Bakker WH, Breeman WA, Kooij PP, Lugtenburg PJ, et al. Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience. Semin Nucl Med 2002;32:110–22.

[47] Anthony LB, Woltering EA, Espenan GD, Cronin MD, Krenning EP. Combination radionuclide therapy using 177Lu-DOTA0,Tyr3-octreotate and (18)F-fluoro-L-dihydroxyphenylalanine positron emission tomography in neuroendocrine tumor patients. Q J Nucl Med Mol Imaging 2010;54:68–75.

[48] Anderson CJ, Dehadschi F, Cutler PD, Schwarz SW, Laforest R, Bass LA, et al. 64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors. J Nucl Med 2001;42:213–21.

[49] Orlefos H, Sundin A, Ahlström H, Bjurling P, Bergström M, Lilja A, et al. Positron emission tomography with 153Sm-carnosine and (153)Sm-DTPA-carnosine and (18)F-fluorodeoxyglucose positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography. J Clin Endocrinol Metab 2005;90:3392–400.

[50] Kjaer B, Villard L, Romer A, Marincek N, Brunner P, Koller MT, et al. Cohort study of somatostatin-based radionuclide therapy. Clin Res 2013;54:1854.
radiopeptide therapy with [(90)Y-DOTA]-TOC versus [(90)Y-DOTA]-TOC plus [(177)Lu-DOTA]-TOC in neuroendocrine cancers. J Clin Oncol 2012;30:1100–6.

[56] Valkema R, Pauwels S, Kvols LK, Barone R, Jamar F, Bakker WH. Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med 2006;36:147–56.

[57] Bushnell DL Jr, O’Dorisio TM, O’Dorisio MS, Menda Y, Hicks RJ, van Cutsem E, et al. 90Y-edotreotide for metastatic carcinoid refractory to octreotide. J Clin Oncol 2010;28:1652–9.

[58] Bodei L, Kidd M, Paganelli G, Grana CM, Drozdov I, Cremonesi M, et al. Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors. Eur J Nucl Med Mol Imaging 2015;42:5–19.

[59] Janson ET, Sorbye H, Welin S, Federspiel B, Grønbæk H, Hellman P, et al. Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. Acta Oncol 2014;53:1284–97.

[60] Knigge U, Hansen CP. Surgery for GEP-NETs. Best Pract Res Clin Gastroenterol 2012;26:819–31.